Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB announced the results of its fully guaranteed rights issue, raising approximately SEK 151 million before transaction costs. The rights issue was subscribed to approximately 67.5%, with the remaining shares allocated to guarantors. This capital increase will strengthen Medivir’s financial position, enabling further development of its oncology pipeline and enhancing its market presence.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company based in Sweden, primarily engaged in the development of innovative treatments for cancer. The company focuses on advancing its proprietary pipeline of oncology drugs to address unmet medical needs in the market.
Average Trading Volume: 806,954
Technical Sentiment Signal: Sell
Current Market Cap: SEK49.07M
Find detailed analytics on MVIR stock on TipRanks’ Stock Analysis page.